-
1
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-42
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
2
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
-
(2006)
Lancet Oncol
, vol.7
, pp. 379-91
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
-
3
-
-
53749085410
-
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
-
Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4579-86
-
-
Marcus, R.1
Imrie, K.2
Solal-Celigny, P.3
-
4
-
-
28544435078
-
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
-
(2005)
Blood
, vol.106
, pp. 3725-32
-
-
Hiddemann, W.1
Kneba, M.2
Dreyling, M.3
-
5
-
-
0020612685
-
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
-
Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737-43.
-
(1983)
Blood
, vol.62
, pp. 737-43
-
-
Carson, D.A.1
Wasson, D.B.2
Taetle, R.3
Yu, A.4
-
6
-
-
0032483010
-
Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c
-
Leoni LM, Chao Q, Cottam HB, Genini D, Rosenbach M, Carrera CJ, Budihardjo I, Wang X, Carson DA. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci U S A 1998;95:9567-71.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 9567-71
-
-
Leoni, L.M.1
Chao, Q.2
Cottam, H.B.3
Genini, D.4
Rosenbach, M.5
Carrera, C.J.6
Budihardjo, I.7
Wang, X.8
Carson, D.A.9
-
7
-
-
28044446541
-
Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years
-
Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442-8.
-
(2005)
Cancer
, vol.104
, pp. 2442-8
-
-
Else, M.1
Ruchlemer, R.2
Osuji, N.3
Del Giudice, I.4
Matutes, E.5
Woodman, A.6
Wotherspoon, A.7
Swansbury, J.8
Dearden, C.9
Catovsky, D.10
-
8
-
-
33751090057
-
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up
-
Gidron A, Tallman MS. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 2006;47:2301-7.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 2301-7
-
-
Gidron, A.1
Tallman, M.S.2
-
9
-
-
0031670669
-
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients
-
Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-15.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3007-15
-
-
Cheson, B.D.1
Sorensen, J.M.2
Vena, D.A.3
-
10
-
-
0028010849
-
Newer purine analogues for the treatment of hairy-cell leukemia
-
Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994;330:691-7.
-
(1994)
N Engl J Med
, vol.330
, pp. 691-7
-
-
Saven, A.1
Piro, L.2
-
11
-
-
67449103121
-
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
-
Tobinai K, Watanabe T, Tanimoto K, et al. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci 2009;100:1344-50.
-
(2009)
Cancer Sci
, vol.100
, pp. 1344-50
-
-
Tobinai, K.1
Watanabe, T.2
Tanimoto, K.3
-
12
-
-
0034096015
-
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study
-
Tondini C, Balzarotti M, Rampinelli I, Valagussa P, Luoni M, De Paoli A, Santoro A, Bonadonna G. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 2000;11:231-3.
-
(2000)
Ann Oncol
, vol.11
, pp. 231-3
-
-
Tondini, C.1
Balzarotti, M.2
Rampinelli, I.3
Valagussa, P.4
Luoni, M.5
De Paoli, A.6
Santoro, A.7
Bonadonna, G.8
-
13
-
-
2942578934
-
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone
-
Armitage JO, Tobinai K, Hoelzer D, Rummel MJ. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int J Hematol 2004;79:311-21.
-
(2004)
Int J Hematol
, vol.79
, pp. 311-21
-
-
Armitage, J.O.1
Tobinai, K.2
Hoelzer, D.3
Rummel, M.J.4
-
14
-
-
0028218049
-
2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma
-
Hoffman M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon LI, Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994;12:788-92.
-
(1994)
J Clin Oncol
, vol.12
, pp. 788-92
-
-
Hoffman, M.1
Tallman, M.S.2
Hakimian, D.3
Janson, D.4
Hogan, D.5
Variakogis, D.6
Kuzel, T.7
Gordon, L.I.8
Rai, K.9
-
15
-
-
77952300539
-
Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
-
Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010;28:2233-8.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2233-8
-
-
Laszlo, D.1
Andreola, G.2
Rigacci, L.3
-
16
-
-
33750579912
-
Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial
-
Jager G, Neumeister P, Quehenberger F, Wohrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-3.
-
(2006)
Ann Oncol
, vol.17
, pp. 1722-3
-
-
Jager, G.1
Neumeister, P.2
Quehenberger, F.3
Wohrer, S.4
Linkesch, W.5
Raderer, M.6
-
17
-
-
48349121596
-
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group
-
Kalinka-Warzocha E, Wajs J, Lech-Maranda E, Ceglarek B, Holowiecki J, Federowicz I, Walewski J, Czyz J, Robak T, Warzocha K. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer 2008;113:367-75.
-
(2008)
Cancer
, vol.113
, pp. 367-75
-
-
Kalinka-Warzocha, E.1
Wajs, J.2
Lech-Maranda, E.3
Ceglarek, B.4
Holowiecki, J.5
Federowicz, I.6
Walewski, J.7
Czyz, J.8
Robak, T.9
Warzocha, K.10
-
18
-
-
6944230907
-
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study
-
Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 2004;80:267-77.
-
(2004)
Int J Hematol
, vol.80
, pp. 267-77
-
-
Ogura, M.1
Morishima, Y.2
Kobayashi, Y.3
-
19
-
-
34347383853
-
Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma
-
Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48:1092-101.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1092-101
-
-
Robak, T.1
Lech-Maranda, E.2
Janus, A.3
Blonski, J.4
Wierzbowska, A.5
Gora-Tybor, J.6
-
20
-
-
1842588045
-
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
-
Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004;45:937-44.
-
(2004)
Leuk Lymphoma
, vol.45
, pp. 937-44
-
-
Robak, T.1
Smolewski, P.2
Urbanska-Rys, H.3
Gora-Tybor, J.4
Blonski, J.Z.5
Kasznicki, M.6
-
21
-
-
0031885544
-
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma
-
Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:850-8.
-
(1998)
J Clin Oncol
, vol.16
, pp. 850-8
-
-
Betticher, D.C.1
von Rohr, A.2
Ratschiller, D.3
-
22
-
-
0036024588
-
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma
-
Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002;38:1739-46.
-
(2002)
Eur J Cancer
, vol.38
, pp. 1739-46
-
-
Rummel, M.J.1
Chow, K.U.2
Karakas, T.3
-
23
-
-
0030013103
-
Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma
-
Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996;14:2139-44.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2139-44
-
-
Saven, A.1
Lee, T.2
Kosty, M.3
Piro, L.4
-
24
-
-
77951628255
-
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
-
Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010;28:1863-9.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1863-9
-
-
Robak, T.1
Jamroziak, K.2
Gora-Tybor, J.3
-
25
-
-
20044368632
-
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma
-
Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704.
-
(2005)
J Clin Oncol
, vol.23
, pp. 694-704
-
-
Czuczman, M.S.1
Koryzna, A.2
Mohr, A.3
-
26
-
-
4344660758
-
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
-
Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654-61.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2654-61
-
-
Zinzani, P.L.1
Pulsoni, A.2
Perrotti, A.3
-
27
-
-
8744274334
-
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71.
-
(2004)
Blood
, vol.104
, pp. 3064-71
-
-
Forstpointner, R.1
Dreyling, M.2
Repp, R.3
-
28
-
-
70349591632
-
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
-
Tobinai K, Ishizawa K, Ogura M, et al. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci 2009;100:1951-6.
-
(2009)
Cancer Sci
, vol.100
, pp. 1951-6
-
-
Tobinai, K.1
Ishizawa, K.2
Ogura, M.3
-
29
-
-
0003477486
-
World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues
-
Jaffe ES, Harris NL, Stein H, Vardiman JW, eds., 3rd edn. Geneva, Switzerland: World Health Organization,
-
Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues, 3rd edn. Geneva, Switzerland: World Health Organization, 2001.
-
(2001)
-
-
-
30
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-55
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
Horton, J.4
Davis, T.E.5
McFadden, E.T.6
Carbone, P.P.7
-
31
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
-
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244-53
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
32
-
-
10744228140
-
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
-
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
-
(2003)
Semin Radiat Oncol
, vol.13
, pp. 176-81
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
-
33
-
-
4444326818
-
Follicular lymphoma international prognostic index
-
Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
-
(2004)
Blood
, vol.104
, pp. 1258-65
-
-
Solal-Celigny, P.1
Roy, P.2
Colombat, P.3
-
34
-
-
0036682214
-
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
-
Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3262-9
-
-
Witzig, T.E.1
Flinn, I.W.2
Gordon, L.I.3
-
35
-
-
33644845422
-
Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma
-
Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2006;24:174-80.
-
(2006)
J Clin Oncol
, vol.24
, pp. 174-80
-
-
Tobinai, K.1
Watanabe, T.2
Ogura, M.3
-
36
-
-
72149085331
-
Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent clorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL): first results from the International Randomized Phase III Trial
-
(suppl) abstr 630.
-
Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliussonet G. Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent clorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL): first results from the International Randomized Phase III Trial. Blood 2007;110:194a; (suppl) abstr 630.
-
(2007)
Blood
, vol.110
-
-
Karlsson, K.A.1
Strömberg, M.2
Jönsson, V.3
Mulligan, S.P.4
Liliemark, J.5
Juliussonet, G.6
-
37
-
-
0028918514
-
Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients
-
Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995;4:385-90.
-
(1995)
Clin Cancer Res
, vol.4
, pp. 385-90
-
-
Liliemark, J.1
Juliusson, G.2
-
38
-
-
18544404548
-
Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4 + lymphocytopenia after treatment
-
Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4 + lymphocytopenia after treatment. Leuk Lymphoma 1999;35:555-65.
-
(1999)
Leuk Lymphoma
, vol.35
, pp. 555-65
-
-
Bastie, J.N.1
Cazals-Hatem, D.2
Daniel, M.T.3
|